Citi Pharma Maintains Steady Profit in 1QFY26 Despite Rising Financial Costs
Citi Pharma Limited posted a profit after tax of Rs203.69 million for 1QFY26, marking a 1% rise from last year. While higher finance costs and reduced other income pressured margins, improved gross profit and lower taxation helped sustain steady earnings.